Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Myelodysplasia risk high in RCC patients

Shenoy N et al. Clinical Genitourinary Cancer, Published online June 28, 2018. https://doi.org/10.1016/j.clgc.2018.06.008

Key clinical point: Patients with a history of renal cell carcinoma have a substantially increased risk of developing myelodysplastic syndromes as compared to the general population. Given the strong association, an unexplained cytopenia in patients with a history of nephrectomy for localized RCC would warrant a strong consideration for a bone marrow biopsy to detect myelodysplasia.

Major finding: The prevalence of myelodysplastic syndromes in patients over 65 years old with a history of nephrectomy for RCC was 8.4 times that of the age-concordant general population based on the Dusseldorf registry (28/6490 or 395/100,000 vs. 47/100,000), and 3.07 times that of the age-concordant patient population at Mayo Clinic (28/6490 or 395/100,000 vs 128.4/100,000. Both differences were statistically significant (P less than 0.001).

Study details: Mayo Clinic’s ‘Advanced Cohort Explorer’ database was used to identify patients with a history of both malignancies. Prevalence of myelodysplastic syndromes was noted in patients aged 65 years and older with a history of nephrectomy for RCC and was compared to the prevalence of myelodysplastic syndromes in the Dusseldorf MDS registry and the general patient population at Mayo Clinic.

Disclosures: The authors had no relevant financial disclosures.

Source: Shenoy N et al. Clinical Genitourinary Cancer, Published online June 28, 2018. https://doi.org/10.1016/j.clgc.2018.06.008

Citation:

Shenoy N et al. Clinical Genitourinary Cancer, Published online June 28, 2018. https://doi.org/10.1016/j.clgc.2018.06.008

This Week's Must Reads

Perioperative radiation therapy underused in elderly patients with soft tissue sarcomas, Venigalla S et al. Intl J Rad Oncology*Biology*Physics; September (102) 2018: 155-165. https://doi.org/10.1016/j.ijrobp.2018.05.019

Age, R0 resection, and adjuvant radiotherapy boost outcomes in myxofibrosarcoma, Boughzala-Bennadji R et al. Intl J Rad Oncology*Biology*Physics; October (102) 2018: 399-406. https://doi.org/10.1016/j.ijrobp.2018.05.055

Tumor size, invasion beyond subcutaneous fat predict adverse outcomes in undifferentiated pleomorphic sarcoma, Winchester D et al. J Am Acad Dermatol. Available online 19 May 2018 https://doi.org/10.1016/j.jaad.2018.05.022

High recurrence rate after pancreaticoduodenectomy for primary retroperitoneal sarcoma, Tseng W et al. European Journal of Surgical Oncology 2018 (44): June; 810-815.

Nivolumab, pembrolizumab successfully used in Kaposi sarcoma, Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.

Must Reads in Renal Cell Carcinoma

In mRCC: Sunitinib alone not inferior to nephrectomy-sunitinib, Méjean A et al. N Engl J Med. 2018 Aug 2. doi: 10.1056/NEJMoa1803675.

Proactive management eases side effects of sunitinib treatment in RCC, Staehler M et al. Ann Oncol. 2018 Aug 23. doi: 10.1093/annonc/mdy329

Red cell distribution width might predict cancer-specific survival in RCC , Życzkowski M et al. Clinical Genitourinary Cancer 2018 June (16), e677-e683. https://doi.org/10.1016/j.clgc.2017.12.003

mRCC: Patients survive longer at high-volume centers, Joshi SS et al. Euro Urol. 2018 Sep;74[3]:387-93.

High PD1 mRNA levels tied to anti-PD1 monotherapy response, Paré L et al. Ann Oncol. 2018 Aug 27. doi: 10.1093/annonc/mdy335.